Largest M&A deals of biopharma companies by value 2023
In 2023, Pfizer acquired Seagen in a deal worth 43 billion U.S. dollars, making it the largest biopharma acquisition deal of the year. Upfront cash and equity equaled the total value. With three deals within the top 10, Bristol Myers Squibb was the most active company.